Kyverna Advances CAR T-Cell Therapy Pipeline with RMAT Designation and Key Milestones — Kyverna Therapeutics, Inc.

Event summary

FDA grants RMAT designation to miv-cel for non-active secondary progressive multiple sclerosis (naSPMS) based on clinical data.
Rolling BLA submission for stiff person syndrome (SPS) on track for Q4 2026 completion, with potential priority review under RMAT designation.
Enrollment in Phase 3 trial for generalized myasthenia gravis (gMG) expected to complete by mid-2027; topline data from longer-term follow-up Phase 2 study due in Q3 2026.
$199.4 million in cash and marketable securities as of June 30, 2026, providing operating runway into 2028.

The big picture

Kyverna is positioning itself as a leader in CAR T-cell therapies for neurologic autoimmune diseases, with strategic milestones that could redefine treatment paradigms. The RMAT designation and rolling BLA submission underscore the company’s focus on expediting regulatory approvals, while its robust cash position provides financial flexibility to pursue multiple indications.

What we're watching

Regulatory Pathway: Whether the RMAT designation will accelerate miv-cel's approval timeline for SPS and naSPMS.
Commercial Readiness: The pace at which Kyverna can scale its commercial operations ahead of a potential 2027 launch for SPS.
Pipeline Expansion: How the exploration of alternative preconditioning regimens and outpatient administration could broaden miv-cel's market potential.